Naveen Pemmaraju: Final Results ph2 RUXO Plus AZA for Patients with Myelofibrosis
Naveen Pemmaraju, Executive Director-Cancer Medicine for MDACC Cancer Network, shared on X:
“Important brand new MPN paper alert Final results ph2 RUXO plus AZA for patients with Myelofibrosis led by Dr Sankalp Arora and Dr Lucia Masarova and Dr Naval Daver.”
Title: Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis
Authors: Sankalp Arora, Jayastu Senapati, Victoria Chu, Naveen Pemmaraju, Prithviraj Bose, Elias Jabbour, Tapan Kadia, Jing Ning, Dyana Saenz, Linghsa Zhou, Habiba Halim, Yesid Alvarado, Maro Ohanian, Courtney DiNardo, Koichi Takahashi, Nitin Jain, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero, Lucia Masarova, Naval Daver
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 28, 2026, 15:10Ify Osunkwo: Strengthening Sickle Cell Care Systems at Global Conference in Nairobi
-
Aug 28, 2026, 15:08Muhammed Safvan: One Drop of Blood Can Tell a Story
-
Aug 28, 2026, 14:52Jessica Lee: Standing Together for Children and Families with Bleeding Disorders
-
Aug 28, 2026, 14:45Daisy Souster: A New Chapter in Bleeding Disorder Advocacy
-
Aug 28, 2026, 14:42Oluwatoyin Iyabode Ajayi: Heavy Periods – When Is Menstrual Bleeding Too Much?
-
Aug 28, 2026, 14:20Alyson Reidy: Factor Man and Community Support Take Center Stage at NBDF 2026
-
Aug 28, 2026, 14:09New Study Highlights Pregnancy Challenges in Inherited Bleeding Disorders – Glanzmann’s Research Foundation
-
Aug 28, 2026, 13:55Swatee C: A Guide to Common Uterine Disorders
-
Aug 28, 2026, 12:14Gathoni Kungu: Run to End Postpartum Hemorrhage and Save Lives